Atherosclerosis (AS), a continual inflammatory vascular illness characterised by arterial wall lipid accumulation, which may trigger cardiovascular and cerebrovascular ailments comparable to coronary heart illness or stroke, represents the principal pathological foundation of cardiovascular ailments and the main international reason behind mortality [1], [2], [3], [4], [5], [6], [7]. Regardless of the supply of assorted lipid-lowering methods, a considerable proportion of sufferers proceed to exhibit residual cardiovascular danger, underscoring the constraints of present therapeutic regimens and their lack of common efficacy [8], [9]. Due to this fact, it’s crucial to seek out new environment friendly therapy methods to scale back blood lipids.
Rising insights into immune metabolic regulation have recognized proliferation-inducing ligand (APRIL), a tumour necrosis issue (TNF) superfamily member encoded by chromosome 17p13.1 (TNFSF13), as a promising therapeutic goal [10], [11], [12]. Mechanistically, APRIL binds with excessive specificity to heparan sulphate proteoglycan-2 (HSPG-2) within the arterial intima, attenuating subendothelial LDL-C retention, a important initiating occasion in AS [11], [13]. It has been demonstrated in preclinical research that the APRIL-HSPG-2 interplay considerably reduces the atherosclerotic burden in murine fashions, suggesting its therapeutic potential via the modulation of lipid deposition [11], [14]. Research have instructed that enhancing the binding between APRIL and proteoglycans may function a novel therapeutic technique for AS [15], [16], [17]. Nevertheless, additional exploration is required to establish whether or not the rise of APRIL can successfully inhibit plaque synthesis via endogenous pathways and thereby deal with AS.
Present therapeutic methods concentrating on AS plaques predominantly give attention to the supply of lipid-dissolving brokers or modulating lipid biosynthesis pathways [18], [19], [20]. Nevertheless, these approaches have limitations in synergistic efficacy and therapeutic effectiveness. Gene remedy affords a promising different by enabling the environment friendly supply of APRIL-encoding nucleic acids to manage lipid metabolic pathways via focused protein expression [21], [22]. Transformative development will be achieved by integrating lipid-clearing performance into the supply vector. Due to this fact, as proven in Fig. 1A, enabling the concurrent elimination of pre-existing lipid deposits and focused suppression of pathological plaque neogenesis via synergistic modulation of ldl cholesterol homeostasis pathways represents an integrative technique for systemic lipid equilibrium.
Polysaccharides, as naturally plentiful biomolecules, have gained substantial consideration in pharmaceutical analysis owing to their inherent biocompatibility and disease-modifying properties [23], [24]. β-cyclodextrin (CD), a cyclic oligosaccharide derived from starch degradation, demonstrates distinctive lipid-dissolving capability via its hydrophobic cavity whereas preserving structural integrity [25], [26], [27], [28]. Moreover, the plentiful hydroxyl teams in its molecular construction present reactive websites for chemical modification and prolong systemic circulation period. A novel therapeutic technique for the regulation of lipid accumulation and irritation could also be proposed by combining atheroprotective APRIL with lipid-sequestering CD.
On this research, we designed and synthesized a collection of dual-regulation therapeutic platforms with various polycation molecular weights and CD grafting densities (Fig. 1B–C). It was engineered by integrating atheroprotective APRIL with lipid-sequestering CD. A plasmid encoding APRIL (pAPRIL) was designed to mediate sturdy in situ expression of the protein, thereby enhancing its therapeutic efficacy. The cationic polymers facilitated electrostatic complexation with pAPRIL, enabling the meeting of a dual-targeting supply system. By way of systematic evaluation of each lipid-dissolving functionality and nucleic acid supply efficiency, we recognized an optimum formulation. In vivo outcomes exhibit that this optimized system mediates twin therapeutic results, successfully combining lipid scavenging with gene supply (Fig. 1C). Molecular dynamics (MD) simulations supplied a complete rationalization of the binding mechanism between CD and lipids, in addition to the auxiliary function of polycations. The efficient clearance of established plaque lipids via CD-mediated solubilisation was noticed, mixed with suppression of nascent lipid formation through modulating the APRIL pathway. This synergistic method represents a breakthrough in AS administration, addressing pathological lipid accumulation and its underlying biosynthetic mechanisms.
